This trial is evaluating whether Seraph-100 + State of the Art Care will improve 2 primary outcomes and 6 secondary outcomes in patients with Septic Shock. Measurement will happen over the course of Discharge from hospital.
This trial requires 15 total participants across 2 different treatment groups
This trial involves 2 different treatments. Seraph-100 + State Of The Art Care is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"When the circulatory system does not produce adequate delivery of oxygen and nutrients to the tissues, ischemia or reperfusion, or both, may occur. Shock is the condition of insufficient blood flow to tissues, resulting in cell damage, organ dysfunction, and eventually death." - Anonymous Online Contributor
"In conclusion, shock can not only be eliminated, but may be effectively reduced. Since there are multiple ways shock can be reduced, such as medication and lifestyle changes, shock can be controlled to be a manageable amount." - Anonymous Online Contributor
"shock typically arises from a traumatic injury or acute medical illness, and can be caused by the absence of blood circulation or from the failure of the heart to pump blood with pressure to its delivery site. Symptoms include palpitations, shortness of breath, chest discomfort, loss of consciousness, seizures, and shock-induced hypovolemic anemia. Cardiac tamponade results in shock from a buildup of gas around the heart. Bleeding can cause shock due to loss of volume of blood, so loss of blood may also result from a large traumatic injury." - Anonymous Online Contributor
"Shock in children can be treated with fluids, medications, and physical stimulation. If other interventions have failed, a child should be transported to a children’s hospital in a level 1 or 2 trauma center. Transfers and trauma may be necessary. The resuscitation team should make clear to parents that there is no cure but this step can prevent complications from the shock itself." - Anonymous Online Contributor
"around 867,000 people in the U.S. seek medical treatment for severe shock between 1994 and 2001, representing about 7% of visits. Despite increasing rates of shock over that time period, the number of people receiving shock treatment is declining. There was also an increase in the utilization of shock care for people aged 65 or older. As the availability of shock treatment becomes more widespread, and utilization remains high, further research should explore whether shock is used appropriately and by whom." - Anonymous Online Contributor
"Symptoms depend on the cause of shock but include vomiting, low blood pressure (below 70 mm Hg), slow heartbeat, dilated pupils, cold and clammy skin, and blue lips/pulse.\n" - Anonymous Online Contributor
"Seraph-100 + state of the art care appears to be beneficial for patients with shock and septic shock. More research is needed to further understand the mechanisms behind this effect in order to replicate these results in a large, multi-centre trial." - Anonymous Online Contributor
"In most treatments, the therapeutic options are based on the clinical use of inorganic salts or oxygen, which do not alter the mechanisms of pathogenesis, and inorganic compounds that increase or decrease the hemodynamic properties of the organism and that act on cellular functions. In recent years, a new pharmacological approach has been developed which is inspired by the discovery that the organism is equipped with an elaborate cellular system of autoregulation which operates on the level of the circulation. It is well known that this autoregulation can be manipulated by injecting several substances and to make some of them block others." - Anonymous Online Contributor
"Improvements in the quality of life of those with severe septic shock were observed with implementation of new treatment guidelines and the administration of Seraph-100." - Anonymous Online Contributor
"Seraph-100 + state of the art care leads to a major reduction in cardiac arrests. Although the risk of cardiac arrest is increased during the start of Seraph-100 therapy, the risk seems to decrease when patients are stabilized and are then treated with Seraph-100 in a clinical trial. Recent findings must be taken into account in discussions about the value of Seraph-100 in pediatric patients." - Anonymous Online Contributor
"Shock as defined by admission to ICU was associated with significant morbidity and mortality. Patients admitted to ICU with a simplified Acuity Score>15 have an in-hospital mortality of 44%. Patients with a simplified Acuity Score>15 are at high risk for early post-ICU neurological injury and are likely to require prolonged ICU admission." - Anonymous Online Contributor
"Many patients still needed to be treated with the use of state of the art care combined with any other treatments. In a recent study, findings did not identify any single treatment that would optimally control both pain and swelling; thus, an effective treatment would require both pain and swelling to be optimally controlled in conjunction with other treatments." - Anonymous Online Contributor